Jazz Pharmaceuticals files Form 144 for insider share sales
Jazz Pharmaceuticals submitted a Section 144 notice listing planned sales of Common Stock by an affiliate and recent dispositions.
Rhea-AI Filing Summary
Jazz Pharmaceuticals submitted a Section 144 notice listing planned sales of Common Stock by an affiliate and recent dispositions. The filing lists three recent sales by Bruce Cozadd of 6,000 shares on 04/01/2026, 6,000 shares on 05/01/2026, and 6,000 shares on 06/01/2026. The filing also records previously issued stock options dated 02/26/2018 (1,335), 03/05/2018 (4,362), and 02/28/2019 (303).
Positive
- None.
Negative
- None.
Insights
Form 144 lists proposed sales and recent insider dispositions totaling 18,000 shares.
The excerpt shows three reported dispositions by Bruce Cozadd of 6,000 shares each on 04/01/2026, 05/01/2026, and 06/01/2026
These filings are administrative notices required to register brokered resale of restricted or control securities. Cash‑flow treatment and whether further sales are planned are not specified in the excerpt.
Section 144 filings document affiliate resale mechanics, not company actions.
Entries list security types (stock options and common shares) and per‑grant share counts with grant dates. The listed stock options (1,335; 4,362; 303) appear as source instruments but the excerpt does not connect them to a specific resale method.
Timing and proceeds allocation are not stated; subsequent SEC filings or broker disclosures may clarify execution details.
Key Figures
Key Terms
Form 144 regulatory
Stock Option financial
Section 144 notice regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Jazz Pharmaceuticals' Form 144 disclose about insider sales?
Does the Form 144 show how much cash Jazz (JAZZ) received from the sales?
Are the securities being sold from option exercises or existing holdings?
Who is the reporting person on this Form 144 for JAZZ?
AI-generated analysis. How Rhea-AI works. Not financial advice.